Ovid Q3 net loss $14.0M ($0.20/share); cash $62.7M; pauses CCM Phase 2, advances OV329/OV350

Ovid Therapeutics Inc.

2024-Q3 EPS reported -$0.24 revenue$223,400,000

Net loss of $14.0M ($0.20 per share) vs $11.3M in Q3 2023; royalty revenue $173K.
Cash and marketable securities $62.7M; expected to fund operations into H2 2026.
Phase 1 MAD study of OV329 progressing; plans to add cohorts for higher dosing; topline data in 2025.
Regulatory application for Phase 1 trial of OV350 (KCC2 direct activator) expected in Q4 2024; first-in-human Q1 2025.
Pause of Phase 2 study of OV888/GV101 in CCM to incorporate competitor trial insights; ROCK2 programs continue.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.